BTK (P190K)

BTK · Variant type: point · HGVS: p.P190K

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Mobocertinib	99.4%	0.6%	97.22
2	Bosutinib	99.0%	1.0%	87.22
3	Pirtobrutinib	99.0%	1.0%	99.49
4	Canertinib	98.9%	1.1%	96.49
5	Zanubrutinib	98.9%	1.1%	98.24
6	Dasatinib	98.7%	1.3%	87.97
7	Ibrutinib	97.8%	2.2%	94.74
8	Entrectinib	97.6%	2.4%	93.69
9	Osimertinib	97.3%	2.7%	97.24
10	Nintedanib	96.4%	3.6%	90.23
11	Acalabrutinib	91.9%	8.1%	99.50
12	Neratinib	88.1%	11.9%	93.18
13	Repotrectinib	87.2%	12.8%	84.21
14	Remibrutinib	84.3%	15.7%	99.50
15	Pacritinib	82.4%	17.6%	88.64
16	Dacomitinib	81.5%	18.5%	97.99
17	Fostamatinib	81.3%	18.7%	96.74
18	Ponatinib	79.2%	20.8%	78.23
19	Vandetanib	70.9%	29.1%	95.74
20	Brigatinib	69.4%	30.6%	82.96
21	Afatinib	67.5%	32.5%	98.50
22	Pralsetinib	63.5%	36.5%	93.43
23	Gilteritinib	63.0%	37.0%	88.97
24	Pemigatinib	60.2%	39.8%	98.23
25	Cabozantinib	53.4%	46.6%	92.73

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Mobocertinib	99.4%	97.4%	+2.0%
Bosutinib	99.0%	99.3%	-0.3%
Pirtobrutinib	99.0%	97.7%	+1.3%
Canertinib	98.9%	99.3%	-0.3%
Zanubrutinib	98.9%	97.4%	+1.5%
Dasatinib	98.7%	99.3%	-0.6%
Ibrutinib	97.8%	98.8%	-0.9%
Entrectinib	97.6%	95.1%	+2.5%
Osimertinib	97.3%	96.3%	+1.0%
Nintedanib	96.4%	98.0%	-1.6%
Acalabrutinib	91.9%	95.9%	-3.9%
Neratinib	88.1%	93.9%	-5.8%
Repotrectinib	87.2%	93.7%	-6.5%
Remibrutinib	84.3%	97.7%	-13.4%
Pacritinib	82.4%	80.3%	+2.0%
Dacomitinib	81.5%	87.2%	-5.7%
Fostamatinib	81.3%	81.5%	-0.2%
Ponatinib	79.2%	—	—
Vandetanib	70.9%	83.8%	-12.9%
Brigatinib	69.4%	—	—
Afatinib	67.5%	88.6%	-21.1%
Pralsetinib	63.5%	—	—
Gilteritinib	63.0%	87.6%	-24.5%
Pemigatinib	60.2%	—	—
Cabozantinib	53.4%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.1ms